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Purpose: Fulranumab is an investigational, fully
human recombinant monoclonal antibody (IgG2) that
neutralizes the biological actions of human nerve
growth factor. Low back pain is a common cause of
noncancer chronic pain and represents one of the most
signiﬁcant socioeconomic health-related problems in
developed countries. This randomized, double-blind,
placebo-controlled study was conducted to evaluate
the analgesic effect of fulranumab in patients with
moderate-to-severe chronic low back pain.
Methods: Patients (aged 18–80 years) were
randomized to receive subcutaneous injections every
4 weeks in 1 of 5 parallel treatment groups: placebo or
fulranumab 1mg (1mgQ4wk), 3mg (3mgQ4wk), 3mg
after a 6mg loading dose (6mgLD+3mgQ4wk), or
10mg (10mgQ4wk) every 4 weeks.
Findings: A total of 385 patients (median age, 53
years; women, 54%) received at least 1 injection of study
medication. No statistically signiﬁcant differences were
observed in improvement of pain intensity scores between
the fulranumab treatment regimens and the placebo
group at week 12 (primary end point; mean [SD],
placebo: −2.0 [2.17], 1mgQ4wk: −1.9 [2.14], 3mgQ4wk:
−2.2 [1.89], 6mgLD+3mgQ4wk: −2.0 [1.72] and
10mgQ4wk: −2.1 [2.18]). Results for secondary efﬁcacy
parameters (change in the Oswestry Disability Index,
Brief Pain Inventory–Short Form, and Patient Global
Assessment scales) were consistent with the primary
outcome. A placebo effect was observed; the overall
percentage of patients with treatment-emergent adverse
events (TEAEs) was similar between the placebo (76%)
and fulranumab treatment groups (77%–90%). AcrossJune 2016all phases, the most common TEAEs in at least 10% of
patients (combined fulranumab group vs placebo) were
arthralgia (15% vs 12%), back pain (15% vs 18%),
upper respiratory tract infection (15% vs 8%), paresthe-
sia (14% vs 8%), diarrhea (12% vs 4%), headache (12%
vs 8%), hypoesthesia (11% vs 5%), pain in extremity
(11% vs 8%), sinusitis (10% vs 5%), and nasopharyng-
itis (10% vs 9%). Across all phases, neurologic TEAEs
were less frequent in the placebo group (14%) versus the
fulranumab treatment groups (25%). In the posttreat-
ment phase, 8 patients had joint replacement operations,
which were considered a result of normal progression of
osteoarthritis. One case in the 10-mg group was deter-
mined to be rapid progession of osteoarthritis and was
considered to be possibly related to study drug.
Implications: Fulranumab did not demonstrate
efﬁcacy compared with placebo in patients with chro-
nic low back pain but was generally well-tolerated.
ClinicalTrials.gov identiﬁer: NCT00973024. (Clin
Ther. 2016;38:1435–1450) & 2016 The Authors.
Published by Elsevier HS Journals, Inc.
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Clinical TherapeuticsINTRODUCTION
Low back pain (LBP) is pain, muscle tension, or
stiffness localized below the costal margin and above
the inferior gluteal folds, with or without referred leg
pain.1 Because of a lack of agreement on its diagnostic
classiﬁcation, the epidemiology of LBP has been
difﬁcult to assess. Nonspeciﬁc chronic LBP (cLBP) is
deﬁned as back pain without a speciﬁc cause when
symptoms persist for 12 weeks or more.2 According to
the 2010 Global Burden of Disease Study, LBP is
among the top 10 diseases and injuries that account
for the highest number of disability-adjusted life-years
worldwide.3 The lifetime prevalence of LBP in
developed countries is estimated to be 60% to
70%.3 Each year, approximately 15% to 45% of
adults have LBP,4 and 5% present to a healthcare
facility with a new episode of back pain.5 Overall,
10% of patients with LBP were unable to work,6 and
approximately 20% had persistent symptoms at
1 year.7 Despite the low proportion of chronic cases,
cLBP accounts for most disability and costs associated
with LBP.8,9 Treatment of this condition is multi-
disciplinary, consisting of pharmacotherapies (eg,
NSAIDs, opioids), antidepressents (eg, duloxetine),
topical ointments, intra-articular injections, nonphar-
macologic treatments (eg, lifestyle modiﬁcation, edu-
cation, exercise), surgical treatment (eg, spinal fusions,
laminectomies, vertebroplasty, or kyphoplasty), and
psychological counseling.10–13 However, pharmaco-
therapies, which are an important component of the
treatment approach, are associated with low toler-
ability due to gastrointestinal, cardiovascular, and
central nervous system disorders.14–16 These tolerabil-
ity issues, along with limited effectiveness (o30%),15
result in insufﬁcient pain relief and reduced treatment
adherence.17,18 In addition, long-term use of opioids
in patients has led to aberrant drug-related behaviors,
including abuse and addiction.19 Given the limitations
and lack of data on long-term effectiveness of the
current therapies, there remains an unmet need for a
tolerable analgesic intervention that is effective in the
treatment of nonspeciﬁc cLBP.
Nerve growth factor (NGF), a neurotrophin, is
associated with inﬂammatory and neuropathic
pain.20–23 An elevated level of NGF, resulting from
tissue damage or other causes, is known to cause pain
and hyperalgesia.20 Rodent studies have found that
antagonism of NGF leads to prevention of pain-
related behavior24–26 and is the rationale for use of1436anti-NGF agents to provide effective relief from
chronic pain. Moreover, blocking NGF’s activity with
anti-NGF antibodies or with IgG fusion proteins
resulted in reduction of hyperalgesia and pain.27–29
Fulranumab is a fully human recombinant mono-
clonal antibody (IgG2) directed against NGF and
speciﬁcally neutralizes the biological activity of human
NGF.30 Recent clinical studies have found that
fulranumab is highly effective in patients for the
treatment of osteoarthritis pain30 and diabetic
peripheral neuropathic pain31 that is inadequately
controlled by standard pain therapies. The present
study was undertaken to evaluate the efﬁcacy and
safety proﬁle of fulranumab when given as an
adjuvant, compared with placebo, in patients with
moderate-to-severe cLBP insufﬁciently controlled by
standard pain therapy (NSAIDs, opioids).METHODS
This was a phase II, randomized, double-blind (DB),
placebo-controlled, dose-ranging, dose-loading study
conducted at 62 sites across 3 countries (Belgium,
Canada, and the United States) from September 2009
through May 2011. The study protocol was approved
by an independent ethics committee or an institutional
review board at each study site, and the study was
conducted in accordance with the ethical principles
that have their origin in the Declaration of Helsinki,
consistent with Good Clinical Practices, and applica-
ble regulatory requirements. Written informed consent
was obtained from all participants at screening before
initiation of protocol-speciﬁed procedures.
Study Population
Male and female patients, 18 through 80 years of
age, with moderate-to-severe cLBP not adequately
controlled by standard analgesic therapy (NSAIDs,
opioids) were enrolled. Patients had a documented
clinical diagnosis of LBP (category 1 or 2, classiﬁed
according to the Quebec Task Force Classiﬁcation for
Spinal Disorders) that was present for Z20 days per
month, Z3 hours per day, or Z6 months; a average
pain intensity rating of Z5 (11-point pain intensity
numerical rating scale [NRS]) during 3 days before
randomization; and Beck Depression Inventory II
score ofr29 at screening. Patients had to be receiving
stable doses of NSAIDs or immediate-release opioids
for a minimum of 5 days per week or long-actingVolume 38 Number 6
P. Sanga et al.opioids (not exceeding 200 mg of oral morphine
equivalents per day) for 4 weeks before screening.
Key exclusion criteria included LBP classiﬁed as
category 3 or 4 by the Quebec Task Force Classiﬁca-
tion for Spinal Disorders; history of seizure disorder,
intrathecal therapy, epidural therapy and ventricular
shunts, mild or moderate traumatic brain injury,
stroke, transient ischemic attack, or meningitis within
the past year before screening; history of brain injury
within the past 15 years, resulting in a change in
consciousness and with residual sequelae history
of epilepsy or multiple sclerosis; current diagnosis
of ﬁbromyalgia, complex regional pain syndrome
(including reﬂex sympathetic dystrophy or causalgia),
acute spinal cord compression, bowel or bladder
dysfunction as a result of cauda equina compression,
back pain caused by secondary infection, or pain
caused by conﬁrmed or suspected neoplasm; and/or
any new or unresolved neurologic deﬁcits, including
progressive deﬁcits, within 6 months before screening.
Study Medication
Study medication was supplied by Amgen Inc
(Thousand Oaks, California). Fulranumab was a
clear, sterile, frozen solution (approximately 1-mL ﬁll
volume) in 5-mL, single-use glass vials. The fulranu-
mab solution contained fulranumab at a concentra-
tion of 10 mg/mL. Matching placebo was supplied as
a clear, sterile solution (approximately 1-mL ﬁll
volume) in 5-mL, single-use glass vials.
Study Design
The planned study consisted of 3-week screening,
12-week DB efﬁcacy, 92-week DB extension, and 26-
week posttreatment phases. All eligible patients were
randomized (1:1:1:1:1) to receive 1 of 5 treatments
(placebo, fulranumab 1 mg every 4 weeks [1mgQ4wk],
3 mg every 4 weeks [3mgQ4wk], 3 mg every 4 weeks
after a 6-mg loading dose [6mgLDþ3mgQ4wk], or 10
mg every 4 weeks [10mgQ4wk]) based on a computer-
generated randomization schedule. The Interactive
Voice Response System assigned a unique treatment
code that was not provided to the investigator. During
the DB efﬁcacy and DB extension phases, the patients
received 1 subcutaneous injection of study medication
in the thigh every 4 weeks. To maintain blinding,
placebo-treated patients were randomly assigned to 1
of the 4 volumes, matching the volumes of the 4
fulranumab treatment groups. The randomization wasJune 2016stratiﬁed by baseline opioid use (yes or no) and body
weight (o85 or Z85 kg). Dose reductions in study
drug were allowed for patients who experienced new or
worsening neurologic treatment-emergent adverse
events (TEAEs). Patients who completed all assessments
during the 12-week DB efﬁcacy phase, including the last
visit (ie, week 13) were considered to have completed
the DB efﬁcacy phase of the study. After completion of
the 12-week DB efﬁcacy phase, efﬁcacy analysis was
performed; dosing was stopped (October 2010) because
of a lack of efﬁcacy. All patients entered the posttreat-
ment phase per protocol, which occurred 2 months
before the clinical hold imposed by the US Food and
Drug Administration on all anti-NGF studies because of
concerns of possible increased risk of osteonecrosis and/
or rapid progression of osteoarthritis (RPOA).Concomitant Medications
The use of NSAIDs, immediate-release opioids,
long-acting opioids, and acetaminophen (paracetamol;
as rescue medication) was permitted. During the
12-week DB efﬁcacy phase, patients were required to
maintain their concurrent pain medications without
change unless indicated for tolerability. However,
they were allowed to change their concurrent pain
medications as clinically needed during the DB
extension phase.Study Evaluations
Efficacy
The primary efﬁcacy objective was the evaluation
of change from baseline to the end of the 12-week
DB efﬁcacy phase in the mean LBP-related pain
intensity score. The mean LBP NRS (0 indicating
no pain to 10 indicating worst pain) during the past
12 hours was recorded twice daily. Baseline was a
mean of 3 days before ﬁrst injection, and the end
point was a mean of the last 7 days during the DB
efﬁcacy phase. Secondary efﬁcacy objectives included
evaluation of the efﬁcacy of fulranumab compared
with placebo as measured by back pain disability
with subscales and total scores of the Oswestry
Disability Index (ODI; weeks 1, 5, 9, 13/discontin-
uation, 17, 25, 33, 41, 49, 57, 65, 73, 81, 89, 97,
and 105/discontinuation), pain severity and pain
interference subscales, and total scores from the Brief
Pain Inventory Short Form (BPI-SF; every 4 weeks)
and Patient Global Assessment (PGA; every 4 weeks).1437
Clinical TherapeuticsThe ODI comprises 10 items or dimensions. Each item
of the ODI score was assigned a score of 0 to 5 for the
6 response alternatives. The ODI total score was
expressed as a percentage and was calculated as
follows: total score ¼ (sum of the nonmissing scores
for individual items/total possible score)  100%,
where total possible score ¼ 5  total number of
completed items.32 The BPI-SF included 4 items that
assessed pain intensity (pain intensity subscales) and 7
items that assessed how much this pain has interfered
with daily activities (pain interference subscales).33
The intensity of pain was assessed with 4 items using
an 11-point NRS from 0 indicating no pain to 10
indicating pain “as bad as you can imagine.” The pain
interference items are scored by the respondent on a
scale of 0 indicating does not interfere to 10 indicating
completely interferes. If any of the individual compo-
nents were missing, then the pain intensity subscale
score was set to missing. The BPI-SF pain interference
subscale score was calculated as the mean of the
nonmissing scores from the individual components.
This mean was computed only if at least 4 of the 7
items were nonmissing.34 The PGA is a single item
that the patients completed to indicate perception of
his or her LBP problem on an 11-point NRS from 0
indicating very good to 10 indicating very bad.
Pharmacokinetic Properties
Pharmacokinetic (PK) end points included evalua-
tion of the PK properties of fulranumab after multiple-
dose administrations of fulranumab and a population
PK approach to characterize the disposition character-
istics of fulranumab in this study. Venous blood
samples for measuring serum fulranumab concentra-
tions were scheduled to be collected at weeks 1, 5, 9,
13, 17, 21, 25, 29, 33, 37, 57, 81, and 105 and at
week 26 after the last dose of study drug. Samples
were collected at the ﬁnal visit for patients who
discontinued from the study. An additional blood
sample was collected randomly at a clinic visit any-
time between week 5 and week 13. Serum fulranumab
concentrations were measured using a validated
ELISA. The lowest quantiﬁable concentration in a
sample for the serum fulranumab ELISA was 0.00156
μg/mL. In addition, serum fulranumab concentrations
were summarized by baseline body weight (o85 or
Z85 kg). Concentrations below the lowest quantiﬁ-
able concentration in a sample were treated as 0 in
these summaries.1438Immunogenicity
Serum samples for the detection of antibodies to
fulranumab were collected at weeks 1, 13, 37, 57, 81,
and 105 and at week 26 after the last dose of study
medication. Samples were collected at the ﬁnal visit
for patients who were terminated from the study. The
presence of antidrug antibodies against fulranumab in
serum was determined by a validated electrochemilu-
minescent immunoassay on a Meso Scale Discovery
platform (Gaithersburg, Maryland). The maximum
observed sensitivity of the serum antidrug antibody
electrochemiluminescent immunoassay was 0.77 ng/mL
at a minimum required 1/20 dilution.
Safety Profile
Safety proﬁle measurements were performed
throughout the study and included evaluations of
TEAEs, monitoring of injection site, clinical labora-
tory tests, ECGs, vital signs, physical examination,
and neurologic assessments (Total Neuropathy Score–
nurse35 and the Mini-Mental State Examination).36 In
addition, examination of joint safety proﬁle was
instituted and included collection of all imaging and
requests for tissue specimens of excised and replaced
joints from the time of the clinical hold until the end of
posttreatment phase. An independent data monitoring
committee was appointed before the start of the study
to review all unblinded safety proﬁle data.
Statistical Evaluations
Sample Size Determination
It was estimated that with 72 patients per group
(360 patients in total) the study would have 84%
power to detect a treatment difference versus placebo
of 1.4 for change from baseline to the end of the
12-week DB phase in average pain intensity score,
assuming an SD of 2.5 for each group and a 20%
withdrawal rate, using a type I error rate of 0.05 and a
2-sided, 2-sample t test.
Analysis Set
All efﬁcacy and safety proﬁle analyses were based
on the intent-to-treat analysis set, which included
all randomly assigned patients who received at least
1 dose of fulranumab or placebo.
Statistical Analyses
Demographic and baseline characteristics were
summarized descriptively. Change from baseline toVolume 38 Number 6
P. Sanga et al.week 12 in average pain score was analyzed using
ANCOVA, with treatment, baseline body weight (o85
or Z85 kg), and baseline opioid use (yes or no) as
factors and baseline average pain score as the covariate.
A step-down procedure was planned, at a 2-sided, 0.05
level of signiﬁcance for each step, in the following order
of fulranumab doses versus placebo: (1) 10mgQ4wk, (2)
6mgLDþ3mgQ4wk, (3) 3mgQ4wk, and (4) 1mgQ4wk.
The primary analysis used the last observation carried
forward imputation method for the missing data. All
analyses based on the last observation carried forward
were also replicated using the baseline observation
carried forward imputation method. Sensitivity analyses
of the primary efﬁcacy results were performed using a
model of mixed-effects repeated measures for observed
cases.
Change from baseline to week 12 in ODI total
scores, pain severity, and pain interference sub-
scales of the BPI-SF and PGA scores were analyzed
using the same ANCOVA, with the corresponding
baseline as a covariate. There were no multiplicity
adjustments for secondary efﬁcacy comparisons.
The incidence and titers of antibodies to fulranu-
mab were summarized by treatment group for
all treated patients. Patients were classiﬁed as
positive or negative for antibodies to fulranumab.
Descriptive statistics were provided for PK data,
and PK end points included mean, SD, median,
and range.
All evaluations for safety proﬁle were summarized
descriptively. The incidence of patients reporting
TEAEs was tabulated by system-organ class and
preferred terms.RESULTS
Patient Disposition and Demographic
Characteristics
Overall, 625 patients were screened, of whom 389
eligible patients were randomly assigned to 5 treat-
ment groups, and 385 patients received at least 1
dose of the study medication (Figure 1). Overall, 330
(84.8%) of 389 randomized patients completed the
DB efﬁcacy phase, and 317 patients entered the DB
extension phase. The major reason for withdra-
wal from the DB extension phase was sponsor
discontinued the study (72%, because of a lack of
efﬁcacy in the DB efﬁcacy phase). Most patients
(76%) completed the posttreatment phase.June 2016Patient demographic characteristics and baseline
characteristics were generally balanced across the
treatment groups (Table I). Among these patients
(mean age, 53.2 years), 54.0% were women, 45.5%
were taking opioids at baseline, and 52.7% were in the
o85 kg subgroup. A total of 51.7% patients had LBP
pain with no radiation, with the highest percentage of
patients in the placebo group (60.5%); a total of
48.1% of patients had LBP with some radiation into
proximal extremity, with the highest percentage of
patients in the fulranumab 1mgQ4wk group (55.8%).
Most patients received 3 injections of the study
medications during the DB efﬁcacy phase (82%–91%),
and most patients (59%–67%) received 6 injections in
the DB extension phase. Six patients did not receive all 3
planned injections (due to neurologic adverse event,
missed visit, or other reasons not provided by the
investigator). Only 1 patient (in the 10mgQ4wk group)
had a dose reduction from the day 29 to the day 57 dose
due to a neurosensory TEAE. The median treatment
duration during the DB phases was similar across
all treatment groups: approximately 9 to 9.4 months
(275–282.5 days), with approximately 3 of those
months during the DB efﬁcacy phase. The duration of
the extension phase that was to be approximately 92
weeks was curtailed because of the early termination of
the study.
No signiﬁcant change from baseline to end of the
DB efﬁcacy phase in the average daily dose of rescue
medication was noted. In the 6mgLDþ3mgQ4wk and
10mgQ4wk fulranumab groups (18.6% each), the
lowest median percentage of days taking rescue
medication was observed compared with the placebo
group (34.5%) and other fulranumab groups (25.0%
[1mgQ4wk] and 22.5% [3mgQ4wk]) during the
entire 12-week DB efﬁcacy phase.Efficacy Outcomes
Primary End Points
No signiﬁcant differences were observed in the imp-
rovement of pain intensity scores between the fulra-
numab treatment regimens compared with the placebo
group at week 12. The least square mean change from
baseline was 1.9 (1mgQ4wk), 2.2 (3mgQ4wk),
2.0 (6mgLDþ3mgQ4wk ), 2.1 (10mgQ4wk ) and
2.0 (placebo) (Table II). The numerical reduction of
pain over time (weeks 4, 8, and 12) with fulranumab
treatment revealed a consistent pattern of improvement1439
Patients randomized in 
double-blind efficacy phase
weeks 1 to 12
n = 389
End-of-phase/early withdrawal
End-of-phase/early withdrawal
Placebo
n = 78
Fulranumab
1mgQ4wk
n = 77
Completed: 65
Withdrawn: 12
Adverse event: 2
Investigator’s 
decision: 0
Lack of efficacy: 3
Lost to follow-up: 1
Patient choice: 3
Other: 3
Completed: 62
Withdrawn: 16
Adverse event: 2
Investigator’s 
decision: 2
Lack of efficacy: 2
Lost to follow-up: 2
Patient choice: 4
Other: 4
Completed: 68
Withdrawn: 9
Adverse event: 0
Investigator’s 
decision: 0
Lack of efficacy: 3
Lost to follow-up: 1
Patient choice: 3
Other: 2
Completed: 68
Withdrawn: 10
Adverse event: 3
Investigator’s 
decision: 0
Lack of efficacy: 0
Lost to follow-up: 1
Patient choice: 2
Other: 4
Completed: 67
Withdrawn: 11
Adverse event: 3
Investigator’s 
decision: 0
Lack of efficacy: 1
Lost to follow-up: 1
Patient choice: 2
Other: 4
Fulranumab
3mgQ4wk
n = 77
Fulranumab
6mgLD+3mgQ4wk
n = 78
Fulranumab
10mgQ4wk
n = 79
Double-blind extension
weeks 13 to 105
n = 317
Posttreatment phase
26 weeks after the last dose
of study drug
Posttreatment phase
26 weeks after the last dose
of study drug
Placebo
n = 62
Fulranumab
1mgQ4wk
n = 61
Unknown: 1
Withdrawn: 61
Adverse event: 2
Death: 0
Investigator’s  
decision: 0
Lack of efficacy: 7
Lost to follow-up: 3
Sponsor 
discontinued 
Study/cohort: 42
Patient choice: 4
Other: 3
Unknown: 0
Withdrawn: 61
Adverse event: 4
Death: 0
Investigator’s  
decision: 3
Lack of efficacy: 2
Lost to follow-up: 1
Sponsor 
discontinued 
Study/cohort: 46
Patient choice: 3
Other: 2
Unknown: 1
Withdrawn: 63
Adverse event: 2
Death: 0
Investigator’s  
decision: 1
Lack of efficacy: 1
Lost to follow-up: 4
Sponsor 
discontinued 
Study/cohort: 45
Patient choice: 9
Other: 1
Unknown: 1
Withdrawn: 66
Adverse event: 3
Death: 0
Investigator’s  
decision: 0
Lack of efficacy: 3
Lost to follow-up: 1
Sponsor 
discontinued 
Study/cohort: 50
Patient choice: 4
Other: 5
Unknown: 0
Withdrawn: 63
Adverse event: 4
Death: 1
Investigator’s  
decision: 3
Lack of efficacy: 0
Lost to follow-up: 4
Sponsor 
discontinued 
Study/cohort: 44
Patient choice: 5
Other: 2
Fulranumab
3mgQ4wk
n = 64
Fulranumab
6mgLD+3mgQ4wk
n = 67
Fulranumab
10mgQ4wk
n = 63
Figure 1. Study design and patient disposition (all randomized patients analysis set). One patient in the 1 mg
of fulranumab every 4 weeks (1mgQ4wk) group never received an injection in the double-blind
extension phase before being withdrawn (reason: other). LD ¼ loading dose.
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Table I. Demographic and baseline characteristics (intent-to-treat analysis set).
Fulranumab
Characteristic
Placebo
(n ¼ 76)
1mgQ4wk
(n ¼ 77)
3mgQ4wk
(n ¼ 77)
6mgLDþ3mgQ4wk
(n ¼ 78)
10mgQ4wk
(n ¼ 77)
Total
(n ¼ 385)
Age, mean (SD), y 54.9 (11.72) 51.7 (11.58) 53.2 (13.46) 54.1 (10.77) 51.9 (12.48) 53.2 (12.03)
Age group, No. (%)
Z65 years 15 (19.7) 13 (16.9) 14 (18.2) 13 (16.7) 15 (19.5) 70 (18.2)
o65 years 61 (80.3) 64 (83.1) 63 (81.8) 65 (83.3) 62 (80.5) 315 (81.8)
Women, No. (%) 43 (56.5) 39 (50.6) 37 (48.1) 47 (60.3) 42 (54.5) 208 (54.0)
Race, No. (%)
White 65 (85.5) 70 (90.9) 64 (83.1) 65 (83.3) 61 (79.2) 325 (84.4)
Black or African American 8 (10.5) 4 (5.2) 7 (9.1) 9 (11.5) 12 (15.6) 40 (10.4)
Asian 2 (2.6) 1 (1.3) 2 (2.6) 2 (2.6) 1 (1.3) 8 (2.1)
American Indian or Alaskan native 0 2 (2.6) 0 1 (1.3) 1 (1.3) 4 (1.0)
Other/multiple 0 0 4 (5.2) 1 (1.3) 1 (1.3) 6 (1.6)
Not reported 1 (1.3) 0 0 0 1 (1.3) 2 (0.5)
Baseline BMI, mean (SD), kg/m2 29.2 (5.28) 29.4 (4.65) 29.2 (4.60) 28.9 (5.45) 28.8 (6.47) 29.1 (5.31)
Strata 1 – baseline opioid use, No. (%)
No opioids 42 (55.3) 42 (54.5) 42 (54.5) 42 (53.8) 42 (54.5) 210 (54.5)
Use of opioids 34 (44.7) 35 (45.5) 35 (45.5) 36 (46.2) 35 (45.5) 175 (45.5)
Strata 2 – baseline weight group, No. (%)
o85 kg 40 (52.6) 41 (53.2) 40 (51.9) 42 (53.8) 40 (51.9) 203 (52.7)
Z85 kg 36 (47.4) 36 (46.8) 37 (48.1) 36 (46.2) 37 (48.1) 182 (47.3)
Quebec Task Force classiﬁcation of spinal
disorder, No. (%)
Low back pain with no radiation 46 (60.5) 33 (42.9) 41 (53.2) 40 (51.3) 39 (50.6) 199 (51.7)
Low back pain with some radiation into
proximal extremity
30 (39.5) 43 (55.8) 36 (46.8) 38 (48.7) 38 (49.4) 185 (48.1)
Low back pain with radiation and positive
neurologic ﬁndings
0 1 (1.3) 0 0 0 1 (0.3)
LD ¼ loading dose; Q ¼ every.
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Table II. Change from baseline to 12-week end point in average pain intensity score (last observation carried
forward) in the intent-to-treat analysis set.
Fulranumab
Variable
Placebo
(n ¼ 76)
1mgQ4wk
(n ¼ 77)
3mgQ4wk
(n ¼ 77)
6mgLDþ3mgQ4wk
(n ¼ 78)
10mgQ4wk
(n ¼ 77)
Baseline, mean (SD) 7.2 (1.20) 6.8 (1.26) 7.0 (1.25) 7.0 (1.06) 7.0 (1.13)
Baseline, median
(range)
7.1 (5–10) 6.8 (5–10) 7.0 (5–10) 6.8 (5–10) 7.0 (5–10)
Week 12, mean (SD) 5.1 (2.29) 4.9 (2.26) 4.8 (2.27) 4.9 (1.94) 4.9 (2.51)
Week 12, median
(range)
5.2 (0–9) 5.0 (1–10) 4.7 (0–10) 5.1 (1–9) 5.0 (0–10)
Change from baseline,
mean (SD)
2.0 (2.17) 1.9 (2.14) 2.2 (1.89) 2.0 (1.72) 2.1 (2.18)
Change from baseline,
median (range)
1.4 (8 to 2) 1.3 (6 to 3) 2.2 (7 to 1) 1.8 (7 to 1) 1.8 (8 to 1)
LS mean change 2.0 1.9 2.2 2.0 2.1
Difference of LS
means (95% CI)
0.04
(0.60 to 0.68)
0.24
(0.88 to 0.40)
0.05
(0.68 to 0.59)
0.15
(0.79 to 0.49)
P value (minus
placebo)*,†
0.91 0.46 0.89 0.65
LD = loading dose; LS = least square; Q = every.
*P values and LS means from ANCOVA model with treatment, baseline opioid use (use/no use), and baseline body weight
(o85 or Z85 kg) as factors and baseline average pain score as covariate.
†Nominal unadjusted P values are presented.
Clinical Therapeuticssimilar to placebo (Figure 2). However, there were no
signiﬁcant changes in average pain intensity for any of
the fulranumab treatment groups versus placebo. The
placebo effect improved over time and reached a least
square mean change from baseline of 2.0 at week 12.
No signiﬁcant change from baseline in average pain
scores across all fulranumab treatment groups
compared with the placebo group at week 12 of the
DB efﬁcacy phase was noted based on the baseline
observation carried forward and mixed-effects re-
peated-measures sensitivity analyses.
Secondary End Points
Across all fulranumab treatment groups, no signiﬁcant
change from baseline to end point in ODI scores was
observed compared with placebo (Table III). However,
numerically greater improvements in scores from baseline
to end point were noted in the 3mgQ4wk and
10mgQ4wk treatment groups compared with placebo.1442For the BPI-SF pain intensity and pain interference
subscale scores, no consistent dose-related improvement
from baseline was observed at the end of the DB efﬁcacy
phase. However, a signiﬁcant improvement from baseline
was observed for the treatment relief in the fulranumab
10mgQ4wk group (mean [SD] change from baseline,
18.0 [34.76]) compared with placebo (mean [SD] change
from baseline, 4.9 [30.56]) (P ¼ 0.008). There were no
signiﬁcant differences versus placebo for changes in PGA
scores from baseline to the end of the DB efﬁcacy phase.
PK Properties
After a subcutaneous injection of fulranumab, mean
trough serum fulranumab concentrations increased in an
approximately dose-proportional or greater than dose-
proportional manner across all dosing regimens (data not
shown). Steady-state serum fulranumab concentrations
were generally achieved by week 17 after 1mgQ4wk,
3mgQ4wk, 6mgLDþ3mgQ4wk, or 10mgQ4wk dosing.Volume 38 Number 6
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Fulranumab 1mgQ4wk (n = 77) −1.46 (0.19) −1.82 (0.23) −1.93 (0.24)
Fulranumab 3mgQ4wk (n = 77) −1.31 (0.16) −1.93 (0.20) −2.23 (0.22)
Fulranumab 6mgLD+3mgQ4wk (n = 78) −1.45 (0.19) −1.77 (0.19) −2.04 (0.19)
Fulranumab 10mgQ4wk (n = 77) −1.24 (0.18) −1.86 (0.21) −2.14 (0.25)
Figure 2. Mean (SE) change from baseline in pain intensity score over time in the double-blind efficacy phase (last
observation carried forward [LOCF]) in the intent-to-treat analysis set. LD ¼ loading dose; Q ¼ every.
P. Sanga et al.Mean trough serum fulranumab concentrations were
generally maintained at an approximate steady-state
through week 37 when treated with 1mgQ4wk,
3mgQ4wk, or 10mgQ4wk maintenance dosing. Within
each treatment group, the mean serum fulranumab
concentrations in patients weighing Z85 kg were gen-
erally lower than those levels observed at each respective
sampling time point in patients weighing o85 kg.
Immunogenicity
Four patients in the fulranumab treatment groups
developed antibodies to fulranumab by the end
of study (data not shown). The incidence of antibodies
to fulranumab occurred in the 1mgQ4wk and
10mgQ4wk dose groups. Overall, antibody responses
to fulranumab were low (titers, 1:20–1:320), and none
of these antibodies were able to reduce serum fulra-
numab concentrations or neutralize the biological
effects of fulranumab in vitro.
Safety Profile Outcomes
Overall, fulranumab at all doses was generally well-
tolerated. During the combined DB and posttreatment
phase, the overall percentage of patients with TEAEs wasJune 2016similar between placebo (76%) and the fulranumab
treatment groups (77%–90%), with no dose relationship
observed among the fulranumab groups (Table IV). In
the combined fulranumab group, upper respiratory tract
infection, sinusitis, nasopharyngitis, back pain, arthralgia,
pain in extremity, peripheral edema, paresthesia,
headache, hypoesthesia, and diarrhea were the most
common TEAEs. Across treatments, during all phases
combined, the percentage of patients discontinuing
due to TEAEs was low (26 patients [7%]), with no
apparent dose relationship. Most TEAEs were mild or
moderate in intensity. Serious TEAEs occurred in 33
patients (1mgQ4wk, 9 [12%]; 3mgQ4wk, 6 [8%];
6mgLDþ3mgQ4wk, 11 [14%]; and 10mgQ4wk, 7
[9%]) in the combined fulranumab group compared
with 7 patients (9%) in the placebo group (Table IV).
Most of the serious TEAEs were in musculoskeletal and
connective tissue disorders and surgical and medical pro-
cedures system organ classes. One death was reported in
the 10mgQ4wk group due to streptococcal pneumonia
and malignant lung neoplasm.
Neurologic TEAEs were more frequent in the
fulranumab treatment groups compared with placebo
(1mgQ4wk, 12 [16%]; 3mgQ4wk, 20 [26%];1443
Table III. Change from baseline to 12-week end point in Oswestry Disability Index, Brief Pain Inventory, and patient global assessment
(last observation carried forward) in the intent-to-treat analysis set.
Fulranumab
Placebo
(n = 76)*
1mgQ4wk
(n ¼ 77)‖
3mgQ4wk
(n ¼ 77)‡
6mgLDþ3mgQ4wk
(n ¼ 78)†
10mgQ4wk
(n ¼ 77)‡
Oswestry Disability Index
Baseline, mean (SD) 36.7 (13.47) 33.5 (12.03) 34.0 (14.0) 37.0 (13.51) 36.8 (13.55)
Baseline, median (range) 35.6 (6–76) 32.0 (4–64) 34.0 (4–72) 35.8 (12–72) 38.0 (8–64)
Change from baseline
Mean (SD) 6.5 (12.64) 5.7 (11.82) 8.0 (12.16) 6.8 (11.35) 7.9 (11.82)
Median (range) 4.4 (58 to 16) 6.0 (38 to 54) 6.0 (42 to 20) 5.2 (32 to 18) 6.0 (48 to 20)
P value (minus placebo)§,‖ 1.00 0.24 0.89 0.47
Difference of LS means (95% CI) 0.0 (3.69 to 3.69) 2.2 (5.90 to 1.50) 0.3 (3.95 to 3.41) 1.4 (5.04 to 2.34)
Brief Pain Inventory–Pain Intensity Subscale
Baseline, mean (SD) 6.7 (1.29) 6.4 (1.25) 6.5 (1.34) 6.5 (1.20) 6.7 (1.28)
Baseline, median (range) 6.8 (3–9) 6.3 (3–10) 6.5 (4–10) 6.5 (4–10) 6.8 (4–10)
Change from baseline
Mean (SD) 1.6 (2.14) 1.8 (2.02) 2.1 (2.10) 1.6 (1.76) 2.1 (2.22)
Median (range) 1.3 (8 to 4) 1.5 (7 to 2) 1.8 (9 to 2) 1.1 (7 to 2) 2.0 (8 to 3)
P value (minus placebo)§,‖ 0.46 0.10 0.72 0.14
Difference of LS means (95% CI) 0.2 (0.88 to 0.40) 0.5 (1.19 to 0.10) 0.1 (0.76 to 0.53) 0.5 (1.13 to 0.16)
Brief Pain Inventory–Pain Interference Subscale
Baseline, mean (SD) 6.0 (1.85) 5.0 (1.89) 5.3 (2.34) 5.8 (1.61) 5.2 (1.78)
Baseline, median (range) 6.0 (1–9) 4.9 (0–9) 5.4 (0–10) 6.1 (1–9) 5.1 (1–9)
Change from baseline
Mean (SD) 1.6 (2.29) 1.4 (2.10) 2.0 (2.18) 1.9 (1.75) 1.6 (1.96)
Median (range) 1.7 (9 to 6) 1.3 (7 to 4) 1.4 (8 to 3) 1.8 (6 to 2) 1.9 (6 to 3)
P value (minus placebo)§,‖ 0.87 0.09 0.36 0.65
Difference of LS means (95% CI) 0.1 (0.70 to 0.59) 0.6 (1.20 to 0.09) 0.3 (0.93 to 0.34) 0.2 (0.80 to 0.49)
Brief Pain Inventory–Treatment Relief, %
Baseline, mean (SD) 38.8 (22.17) 39.3 (26.04) 35.3 (22.14) 34.7 (22.48) 37.3 (24.46)
Baseline, median (range) 40.0 (0–80) 40.0 (0–100) 30.0 (0–80) 30.0 (0–90) 40.0 (0–90)
Change from baseline
Mean (SD) 4.9 (30.56) 11.6 (32.66) 10.1 (33.83) 8.9 (25.90) 18.0 (34.76)
Median (range) 10.0 (70 to 90) 10.0 (70 to 90) 10.0 (80 to 90) 0.0 (80 to 80) 20.0 (70 to 100)
P value (minus placebo)§,‖ 0.13 0.49 0.73 0.01¶
Difference of LS means (95% CI) 6.9 (2.12 to 15.85) 3.2 (5.84 to 12.21) 1.6 (7.42 to 10.58) 12.1 (3.12–21.15)
Patient Global Assessment
Baseline, mean (SD) 6.9 (1.50) 6.5 (1.49) 6.8 (1.59) 6.8 (1.29) 6.9 (1.41)
Baseline, median (range) 7.0 (3–10) 7.0 (3–10) 7.0 (3–10) 7.0 (4–10) 7.0 (3–10)
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June 20166mgLDþ3mgQ4wk, 21 [27%]; 10mgQ4wk, 24
[31%]; and placebo, 11 [14%]). The most frequently
occurring neurologic TEAEs were paresthesia (com-
bined fulranumab group, 14%; placebo, 8%) and
hypoesthesia (combined fulranumab group, 11%;
placebo, 5%). Two events were considered serious
(lumbar radiculopathy in the 6mgLDþ3mgQ4wk
group and peripheral neuropathy in the 10mgQ4wk
group). A low percentage of patients receiving fulra-
numab (total 1%) discontinued treatment because of
neurologic events (paresthesia, hypoesthesia, periph-
eral neuropathy, peripheral sensory neuropathy, and
muscular weakness). None of the neurologic TEAEs
were serious except for 1 event in the 10mgQ4wk
group (peripheral neuropathy), and that patient re-
covered. The overall percentage of patients with
bradycardia-related TEAEs in all phases combined
was low among the fulranumab treatment groups
(2%) with a higher percentage than placebo
(1 [1%]) in the 3mgQ4wk (3 [4%]) and 10mgQ4wk
(2 [3%]) groups and an equal percentage in
6mgLDþ3mgQ4wk group. None of the patients in
1mgQ4wk had bradycardia-related TEAEs. There
were no TEAEs of bradycardia that were serious or
led to discontinuation. Hypotension-related TEAEs
occurred in 3 of the fulranumab treatment groups
(3mgQ4wk, 1 [1%]; 6mgLDþ3mgQ4wk, 1 [1%];
and 10mgQ4wk, 2 [3%]). One case of hypotension
was considered serious, and no cases of hypotension
led to treatment discontinuation. Elevated aspartate
transaminase and alanine transaminase levels (Z5 the
upper limit of normal) occurred in 3 patients
(1mgQ4wk, 2; placebo, 1). There was no acute renal
failure during the study in any treatment group.
Injection-site evaluations of mild or moderate rating
were most common in the 10mgQ4wk group: 36% of
patients had at least 1 evaluation of mild redness, and
16% had at least 1 evaluation of mild or moderate
swelling in this group during the DB efﬁcacy phase. No
clinically signiﬁcant changes in laboratory parameters,
ECG readings, or vital signs were noted in any patient
during the study. In addition, there were no clinically
signiﬁcant changes from baseline in Total Neuropathy
Score–nurse and Mini-Mental State Examination. Neuro-
logic TEAEs leading to a neurologic consultation with
category grades 42 were noted in the 1mgQ4wk group
(hypoesthesia, muscular weakness, and hypersensitivity,
1 patient each) and the 6mgLDþ3mgQ4wk group
(hypoesthesia and radiculopathy, 1 patient each). The1445
Table IV. TEAEs for all treatment groups for all combined phases.
TEAE
Placebo
(n = 76),
No. (%)
Fulranumab, No. (%)
1mgQ4wk
(n = 77)
3mgQ4wk
(n = 77)
6mgLDþ3mgQ4wk
(n = 78)
10mgQ4wk
(n = 77)
Total patients with TEAEs 58 (76) 59 (77) 64 (83) 70 (90) 66 (86)
Serious TEAEs 7 (9) 9 (12) 6 (8) 11 (14) 7 (9)
TEAEs leading to discontinuation 5 (7) 6 (8) 2 (3) 6 (8) 7 (9)
TEAEs reported by Z10% of
patients in any group
Back pain 14 (18) 15 (19) 11 (14) 10 (13) 11 (14)
Arthralgia 9 (12) 13 (17) 12 (16) 14 (18) 7 (9)
Sinusitis 4 (5) 11 (14) 4 (5) 11 (14) 5 (6)
Pain in extremity 6 (8) 9 (12) 1 (1) 11 (14) 12 (16)
Upper respiratory tract
infection
6 (8) 8 (10) 14 (18) 12 (15) 11 (14)
Headache 6 (8) 8 (10) 10 (13) 9 (12) 9 (12)
Nasopharyngitis 7 (9) 5 (6) 11 (14) 7 (9) 7 (9)
Diarrhea 3 (4) 7 (9) 11 (14) 8 (10) 11 (14)
Edema peripheral 3 (4) 5 (6) 5 (6) 9 (12) 8 (10)
Neurologic TEAEs Z10% of
patients
Paresthesia 6 (8) 5 (6) 16 (21) 12 (15) 10 (13)
Hypoesthesia 4 (5) 4 (5) 10 (13) 8 (10) 12 (16)
LD = loading dose; TEAE = treatment-emergent adverse event; Q = every.
Clinical Therapeuticsincidence rate of joint replacement was 22 per 1000
person-years with fulranumab treatment (combined) and
13 per 1000 person-years with placebo treatment. An
adjudication committee consisting of an expert, independ-
ent, and blinded panel was convened to adjudicate all
joint replacement cases and cases with TEAEs that
indicated possible joint destruction but without requiring
joint replacement. In the posttreatment phase, 8 patients
(placebo, 1; combined fulranumab, 7) had joint replace-
ment operations of either the hip or knee or shoulder
arthroplasty. Most of these cases (n¼5) were determined
by the adjudication committee to be from normal
progression of osteoarthritis. One case that was adjudi-
cated as RPOA occurred in a patient taking fulranumab
(10mgQ4wk group) using regular concurrent NSAIDS
and who had a history of osteoarthritis in the affected
joint before study entry. Most joint replacements (n ¼ 6)
were assessed as not related to study drug; 1 (RPOA) was1446assessed as possibly related, and 1 was considered to have
insufﬁcient data for assessment of association.DISCUSSION
Inhibition of NGF by fulranumab, a fully human
recombinant monoclonal antibody, can result in re-
duction of chronic pain resulting from osteoarthritis30
and diabetic peripheral neuropathy31 and is thus
proving to be a promising target in the search for
new pain therapeutics. This dose-ranging, dose-
loading study was conducted to evaluate the efﬁcacy
and safety proﬁle of fulranumab when given as
adjuvant compared with placebo in patients with
moderate-to-severe cLBP insufﬁciently controlled by
standard pain therapy. However, the primary objec-
tive to indicate that fulranumab was signiﬁcantly
better than placebo as measured by the change inVolume 38 Number 6
P. Sanga et al.average pain intensity at the end of the 12-week DB
efﬁcacy phase was not achieved.
The total treatment exposure was curtailed because
the study was terminated while patients were in the
DB extension phase because of a negative efﬁcacy
outcome after the completion of the DB efﬁcacy phase.
However, most of the patients completed the DB
extension phase of up to 12 months of exposure.
Therefore, substantial treatment exposure data for the
safety proﬁle were collected in addition to that during
the posttreatment phase.
The numerical reduction of pain over time (weeks
4, 8, and 12) with fulranumab treatment revealed a
consistent pattern of improvement similar to placebo.
However, there were no signiﬁcant changes in average
pain intensity for any of the fulranumab treatment
groups compared with placebo. The placebo effect
was strong in this study, improving over time and
reaching a least square mean change from baseline of
2.0 at week 12. No dose response was observed in
the primary end point among the fulranumab treat-
ment groups. No signiﬁcant results with fulranumab
in secondary outcomes as measured by change from
baseline in the ODI, BPI-SF subscales, and PGA scales
were seen for any of the 4 treatment groups compared
with placebo. These ﬁndings are in contrast to the
earlier studies that evaluated the effectiveness of
similar anti-NGF class treatment in patients with
chronic osteoarthritis of the knee. In addition, a
previous study on the efﬁcacy and tolerability of
fulranumab in patients with diabetic peripheral neuro-
pathic pain found a mean reduction of average daily
pain at week 12 compared with baseline and revealed
a positive dose-response relationship.31
The mean trough serum fulranumab concentrations
increased in a greater than dose proportional manner
when comparing serum fulranumab concentrations in
the 3mgQ4wk or 10mgQ4wk groups with those in the
1mgQ4wk group. Sparse sampling design, moderate-
to-large interpatient variability in trough serum fulra-
numab concentrations, a large window for sample
collection, and early termination of administration of
the study drug may contribute as a whole to the
variability in serum fulranumab concentrations. Thus,
a deﬁnite conclusion regarding dose proportionality
cannot be drawn. The steady-state serum fulranumab
concentrations were achieved and maintained in those
patients who tested positive for antibodies to fulranu-
mab (low titers), indicating that development ofJune 2016antibodies to fulranumab did not reduce serum fulra-
numab concentrations. However, these results should
be interpreted with caution because only 4 patients in
the active treatment groups tested positive for anti-
bodies to fulranumab through the end of the study.
During the combined DB and posttreatment phases,
the overall rate of TEAEs was similar among placebo
and fulranumab treatment groups, with no dose rela-
tionship apparent. This safety proﬁle is similar to
previous fulranumab studies.30,31 The most frequently
occurring TEAEs were seen in infections and infesta-
tions, musculoskeletal and connective tissue disorders,
nervous system disorders, and gastrointestinal disorders
system organ classes. These TEAEs have also been
reported previously in an earlier study that evaluated
the tolerability of fulranumab in the treatment of osteo-
arthritis.30 The rate of neurologic TEAEs in the placebo
group was less than that in the combined fulranumab
groups. Most of these neurologic TEAEs generally were
mild to moderate in severity and were those associated
with large- and small-ﬁber sensory function, such as
paresthesia and hypoesthesia. These results were con-
sistent with earlier studies in patients with osteoarthritis
pain and diabetic peripheral neuropathic pain.30,31 Few
withdrawals from the study resulted from these TEAEs.
Administration of the anti-NGF class is known to be
associated with a number of clinical events termed
‘events of interest’, such as bradycardia, hypotension,
neurologic signs or symptoms, renal failure, and hepatic
failure. No events of interest were due to study drug as
judged by an unblinded independent data monitoring
committee. There was 1 death in the fulranumab group
due to the serious TEAE of streptococcal pneumonia
and malignant lung neoplasm.
The US Food and Drug Administration has identi-
ﬁed rapid joint destruction and/or osteonecrosis as a
speciﬁc tolerability concern for the anti-NGF class.37
RPOA has been described in the literature for decades
predating the trials of anti-NGF compounds. The
incidence of RPOA in the general osteoarthritis
population has not been well deﬁned. Progression of
osteoarthritis is more rapid than routine osteoarthri-
tis.38 The single case of RPOA reported in this
study appears to be associated with fulranumab and
in patients with preexisting osteoarthritis. Data
elucidating the underlying mechanism of NGF class
inhibition and RPOA are not available. Future studies
examining the link between the NGF class and RPOA
are warranted.1447
Clinical TherapeuticsA limitation of the study was that the study was
terminated prematurely (sponsor’s decision because of the
lack of efﬁcacy results from the DB efﬁcacy phase).
However, the DB efﬁcacy phase was completed, and
efﬁcacy and safety proﬁle were evaluated. Another
limitation of the study is that a high placebo effect was
observed. In recent years, in multiple clinical trials of
neuropathic pain, a placebo response is increasingly
observed, leading to lower separation between the drug
and placebo arms.39–41CONCLUSION
Analgesic efﬁcacy of adjunctive fulranumab at a dose
of up to 10 mg once every 4 weeks during a 12-week
period was not signiﬁcantly different from placebo in
patients with moderate-to-severe cLBP. Fulranumab at
all doses was generally well-tolerated.ACKNOWLEDGMENTS
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